Business
Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI(TM)
Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™ ...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen4{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n LAVAL, QC\n \n ,\n \n May 5, 2021\n \n /CNW Telbec/ - Bausch Health,\n \n Canada\n \n , which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (\"Bausch Health\" or the \"Company\") today announced that Health Canada has approved the use of BRYHALI (Halobetasol Propionate Lotion 0.01% w/w), a high to super-high potency topical corticosteroid indicated for Corticosteroid-Responsive Dermatoses and the topical treatment of plaque psoriasis.i Some of the most \"commonly-encountered skin disorders under the Corticosteroid-Responsive Dermatoses umbrella include seborrheic dermatitis and eczematous dermatoses such as atopic dermatitis and contact dermatitis.\"\n \n ii\n \n \n \n \n \n \n \n \n \n \n BRYHALI lotion is formulated with PRISMATREX™  technology, a novel polymeric emulsification system, which provides a stable condition where emulsion droplets retain their distribution across time and temperature.\n \n iii\n \n BRYHALI is applied once daily and can be used for up to eight weeks.\n \n \n \"With Health Canada's approval of BRYHALI, patients suffering from corticosteroid-responsive dermatoses and will soon have an innovative topical treatment...